Genomma Lab Internacional. de Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Juan Marco Sparvieri

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	1.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

Investors Appear Satisfied With Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Prospects

Dec 02

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Oct 17

Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

Sep 11

With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

Jul 12

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

May 31

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Jan 29

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Nov 07

Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Mar 31

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Feb 24

Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Dec 07

Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Sep 24

Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

Aug 01

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Jul 27

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Mar 22

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Feb 15

Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Nov 24

Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock

Sep 08

Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price

Jun 10

Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?

May 24

Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?

May 06

Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%

Mar 13

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Feb 19

Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?

Feb 02

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?

Jan 15

What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?

Dec 28

Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain

Dec 10

CEO

Juan Marco Sparvieri

1.8yrs

Görev süresi

Mr. Juan Marco Sparvieri servds as an Executive Vice-President and Chief Operating Officer at Genomma Lab Internacional, S.A.B. de C.V. until April 2023 and serves as its Chief Executive Officer since Apri...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rodrigo Alonso Aspra	Founder & Chairman of the Board	16.6yrs	Veri yok	32.58% MX$ 7.9b
Joaquín Ley Pinto	Independent Board Member	less than a year	Veri yok	Veri yok
Jorge Gutierrez Munoz	Independent Director	10.7yrs	Veri yok	Veri yok
Juan Alonso	Independent Director	16.6yrs	Veri yok	Veri yok
Marco Forastieri Muñoz	Independent Proprietary Board Member	4.7yrs	Veri yok	Veri yok
Sabrina Herrera Aspra	Proprietary Director	13.8yrs	Veri yok	Veri yok
Jorge Luis Valderrama	Active Vice Chairman	1.9yrs	Veri yok	Veri yok
Javier Vale Castilla	Independent Director	8.7yrs	Veri yok	Veri yok
Ignacio González Rodríguez	Independent Director	7.7yrs	Veri yok	Veri yok
Juan Gavito Aspe	Patrimonial Independent Director	7.7yrs	Veri yok	Veri yok
Carlos Vara Alonso	Independent Director	6.7yrs	Veri yok	Veri yok
Simona Viztozova	Independent Director	less than a year	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: LAB B 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 19:09
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Genomma Lab Internacional, S.A.B. de C.V. 16 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Antonio Hernandez Velez Leija	Actinver Case de Bolsa, S.A. de C.V.
Benjamin Theurer	Barclays
Miguel Ulloa Suárez	BBVA Corporate and Investment Bank

Genomma Lab Internacional. de Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes

Insufficient new directors

Insufficient new directors

Recent updates

Now 21% undervalued

Third quarter dividend of Mex$0.20 announced

Price target increased by 8.1% to Mex$26.83

Investors Appear Satisfied With Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Prospects

New minor risk - Share price stability

Now 21% undervalued

Consensus EPS estimates increase by 19%

Price target increased by 9.1% to Mex$26.00

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 23, 2024

Genomma Lab Pharma Manufacturing Facility Receives Pending GMP Certification for the Mexican Market from the Mexican Ministry of Health's Federal Committee

Consensus EPS estimates increase by 18%

Price target increased by 9.9% to Mex$21.43

Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024

Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend

Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

Price target decreased by 8.4% to Mex$20.03

First quarter 2024 earnings: Revenues exceed analyst expectations

Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 24, 2024

Genomma Lab Internacional, S.A.B. De C.V. Declares Cash Dividend

Full year 2023 earnings released: EPS: Mex$1.08 (vs Mex$1.40 in FY 2022)

Consensus EPS estimates fall by 21%

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 21, 2024

Genomma Lab Internacional, S.A.B. De C.V. Announces Sixth Dividend Payment

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Third quarter 2023 earnings released: EPS: Mex$0.39 (vs Mex$0.40 in 3Q 2022)

Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: Mex$0.43 (vs Mex$0.40 in 2Q 2022)

Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023

First quarter 2023 earnings released

Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 7.4% to Mex$22.78

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Full year 2022 earnings released: EPS: Mex$1.40 (vs Mex$1.30 in FY 2021)

Now 22% undervalued

Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 22, 2023

Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Genomma Lab Internacional, S.A.B. de C.V. Announces Management Changes

Insufficient new directors

Upcoming dividend of Mex$0.38 per share

Third quarter 2022 earnings released: EPS: Mex$0.40 (vs Mex$0.39 in 3Q 2021)

Genomma Lab Internacional, S.A.B. De C.V. Cash Dividend

Genomma Lab Internacional, S.A.B. de C.V. to Report Q3, 2022 Results on Oct 26, 2022

Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 15%

Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Genomma Lab Internacional, S.A.B. de C.V. to Report Q2, 2022 Results on Jul 27, 2022

Genomma Lab Internacional, S.A.B. de C.V. Declares Second Cash Dividend Payment

Consensus EPS estimates fall by 15%

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Genomma Lab Internacional, S.A.B. de C.V. to Report Q1, 2022 Results on Apr 27, 2022

Consensus EPS estimates increase by 14%

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Genomma Lab Internacional, S.A.B. de C.V. to Report Q4, 2021 Results on Feb 23, 2022

Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Third quarter 2021 earnings released: EPS Mex$0.39 (vs Mex$0.40 in 3Q 2020)

Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock